DLA Piper has advised Breffi on a RUB 750 million investment from Elbrus Capital. O2 Consulting reportedly advised Elbrus Capital on the deal.
Breffi is a Russian omnichannel pharmaceutical marketing company. Founded in 2012 by Evgeniy Gordeev and Irina Shramova, both former employees of AstraZeneca, Breffi focuses on the promotion of pharmaceutical brands primarily through the doctors' community via remote and digital channels. Breffi’s revenue in 2021 exceeded RUB 500 million.
Elbrus Capital is a Russia and CIS-focused private equity firm.
According to DLA Piper, “the funding received from Elbrus Capital will be used to further develop Breffi’s operations, including the scaling up of its services, expansion into an adjacent market, and the enhancement of IT products development.”
DLA Piper’s Moscow-based team was led by Partner Leo Batalov and included by Legal Director Andrei Sheetkin, Associate Alexandra Braterskaya, and Paralegal Alexandra Khvorostyanova.
